Company intelligence / Profile preview

Adjuvax LLC

Birmingham, Alabama, United Statesadjuvax.net ↗

Ownership: Private
Development stage: Preclinical

Overview

Adjuvax develops novel, structurally defined saponin-based adjuvants designed to improve the potency, cost-effectiveness, and accessibility of vaccines. Their work aims to enhance immune responses and reduce antigen doses required in vaccines. No specific clinical results or late-stage programs are publicly disclosed as of June 2025.

Therapeutic areas: Infectious Diseases
Modalities: Vaccine adjuvants (specifically saponin-based)
Industry: Biotech

Drug pipeline

5 assets

VSA-2 adjuvant

Unknown

4 more assets in the full pipeline.

Request access →

Partnerships

Receives federal contracts from the U.S. Department of Health and Human Services and other government agencies for R&D support.

Beyond the preview

Go deeper on Adjuvax LLC.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adjuvax LLC.

Explore the full profile